Clinical Trials Browser

Breast Neoplasms, Neoplasm Metastasis

NCT01579734 2023-06-28

HOT

Phase 3 Unknown

1,884 enrolled

Breast

Breast Neoplasms

NCT00412022 2023-03-24

HOBOE

Phase 3 Unknown

1,294 enrolled

Breast

Breast Neoplasms

NCT02914158 2023-01-17

ASPAIT

Phase 3 Unknown

680 enrolled

Breast

Breast Neoplasms

NCT02062489 2022-04-27

Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

Phase 3 Unknown

688 enrolled

Breast

Breast Neoplasms

NCT05016349 2021-08-23

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Phase 3 Unknown

160 enrolled

Breast

Breast Cancer Female

NCT01758146 2020-03-04

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

Phase 3 Unknown

412 enrolled

BreastOther

Breast Neoplasms, Obesity

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Phase 3 Unknown

3,697 enrolled

Breast

Breast Neoplasms

NCT04046159 2019-08-06

Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

Phase 3 Unknown

810 enrolled

Breast

Carcinoma, Intraductal, Noninfiltrating

NCT03137368 2018-10-31

STEP

Phase 3 Unknown

300 enrolled

Breast

Breast Neoplasms

NCT03351062 2017-11-22

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Phase 3 Unknown

844 enrolled

Breast

Breast Neoplasms

NCT02097459 2016-05-25

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

Phase 3 Unknown

600 enrolled

Breast

Breast Neoplasms

NCT00003418 2013-12-19

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer

Phase 3 Unknown

4,400 enrolled

Breast

Breast Neoplasms

NCT00003678 2013-12-19

Tamoxifen in Treating Women With Breast Cancer

Phase 3 Unknown

20,000 enrolled

Breast

Breast Neoplasms

NCT00010140 2013-12-18

Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer

Phase 3 Unknown

Breast

Breast Neoplasms

NCT00003679 2013-11-06

Combination Chemotherapy in Treating Women With Breast Cancer

Phase 3 Unknown

350 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00003680 2013-11-06

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

Phase 3 Unknown

300 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01622361 2013-09-30

NEST

Phase 3 Unknown

290 enrolled

Breast

Breast Neoplasms

NCT00002460 2013-08-07

Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer

Phase 3 Unknown

Breast

Breast Neoplasms

NCT00006030 2013-08-07

Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer

Phase 3 Unknown

Breast

Breast Neoplasms

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Phase 3 Unknown

2,500 enrolled

Breast

Breast Neoplasms

NCT00963209 2013-08-02

Tamoxifen Citrate in Patients With Breast Cancer

Phase 3 Unknown

140 enrolled

Breast

Breast Neoplasms

NCT00896155 2011-08-30

CONSET

Phase 3 Unknown

260 enrolled

Breast

Breast Neoplasms, Pulmonary Fibrosis

NCT00912548 2009-06-16

ASTRRA

Phase 3 Unknown

1,234 enrolled

Breast

Breast Neoplasms

NCT00003016 2009-02-09

Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer

Phase 3 Unknown

20,000 enrolled

Breast

Breast Neoplasms

Clinical Trials

PATHWAY

HOT

HOBOE

ASPAIT

Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

STEP

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer

Tamoxifen in Treating Women With Breast Cancer

Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer

Combination Chemotherapy in Treating Women With Breast Cancer

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

NEST

Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer

Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Tamoxifen Citrate in Patients With Breast Cancer

CONSET

ASTRRA

Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer